Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
ALIM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading ALIM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.16%70.550.9%$746.71m
AMGNAmgen Inc.
0.00%170.851.1%$707.06m
CELGCelgene Corporation
0.00%130.931.1%$645.79m
REGNRegeneron Pharmaceuticals, Inc.
0.00%502.122.7%$590.62m
BIIBBiogen Inc.
0.00%271.251.2%$491.73m
ALXNAlexion Pharmaceuticals, Inc.
-1.24%120.601.9%$445.24m
VRTXVertex Pharmaceuticals Incorporated
0.00%129.231.9%$271.19m
INCYIncyte Corporation
0.00%130.312.6%$256.98m
CLVSClovis Oncology, Inc.
0.00%89.9618.0%$244.46m
TSROTESARO, Inc.
0.00%141.0314.7%$243.48m
BLUEBluebird Bio, Inc.
0.37%107.3019.3%$160.58m
ILMNIllumina, Inc.
0.00%176.363.5%$150.43m
KITEKite Pharma, Inc.
0.00%98.0516.1%$139.68m
EXASExact Sciences Corporation
0.00%34.0926.3%$128.59m
AAgilent Technologies, Inc.
0.00%58.871.5%$122.37m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.,005X7Z-E